Cytokinetics(US:CYTK) Globenewswireยท2025-11-03 22:26Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, alleging that the company made materially false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten, leading to significant investor losses [8]. Allegation Details - The lawsuit claims that Cytokinetics misrepresented the expected timeline for FDA approval of aficamten, stating it would occur in the second half of 2025, while failing to disclose risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [8]. - On May 6, 2025, it was revealed during an earnings call that the company had discussions with the FDA about safety monitoring but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [8]. Next Steps - Investors who purchased Cytokinetics shares between December 27, 2023, and May 6, 2025, and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][8]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 17, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].